A large British study published today concluded that the mixture of Corona antibodies produced by the “Regeneron” pharmaceutical company reduced the number of deaths of patients in hospitals whose bodies did not produce antibodies.
The treatment, known as “Regin Cove”, has been approved for emergency use in the United States for people with mild to moderate symptoms, but results from the (Recovery) trial provide the clearest evidence of its effectiveness for patients receiving hospital treatment.
The experiment found that antibody treatment reduced the number of deaths that occurred within 28 days of establishing infection with the Corona virus by a fifth, among patients who were being treated in hospitals and whose immune system did not respond by producing antibodies.
The researchers said that this result means six fewer deaths among every 100 patients with the condition who received this treatment.
“People were very, very pessimistic about the effectiveness of any antiviral treatment for this particular virus after patients were admitted to the hospital,” Martin Landray, the lead researcher who participated in the experiment, told reporters.
“If you don’t produce antibodies on your own, it will really help you to get some,” he added.
He added that the treatment also shortened the length of stay in the hospital and reduced the likelihood of them needing respirators.